Publications
Bicaval TricValve Tricuspid Regurgitation: Late-Breaking PCR London Valves 2024
Source DATA presented at PCR London Valves 2024 showed that caval valve implantation (CAVI) with the TricValve system demonstrates an acceptable safety profile and significant clinical benefits in highly comorbid patients with severe
Tricuspid Regurgitation
In this short summary, Hon. Prof. Dr. Katharina Kiss talks about what you need to know about tricuspid regurgitation and current therapy options. Read Here
Interventional Treatment of Severe Tricuspid Regurgitation
In February 2018, a new article by Professor Lauten et al was published: Interventional Treatment of Severe Tricuspid Regurgitation. Early Clinical Experience in a Multicenter, Observational, First-in-Man Study. Transcatheter caval valve implantation
PRESS RELEASEs
P&F USA secures FDA approval for expansion of the TRICAV I study for severe Tricuspid Regurgitation
On December 19, 2024, the US Food and Drug Administration (FDA) approved the expansion of the TRICAV I study for the TricValve® Transcatheter Bicaval Valve System* from 15 patients to 50 patients
More minimally invasive treatment options available in S’pore for patients with leaky heart valve
SINGAPORE – Patients with leaky heart valve have more minimally invasive options to treat the condition, after two new procedures were introduced at the National Heart Centre Singapore (NHCS). Also known as
P&F Products & Features goes U.S. – first implantation of the TricValve® Transcatheter Bicaval Valves System
Vienna, Feburary 24th 2022 TricValve® Transcatheter Bicaval Valves System Today, P&F Products & Features GmbH announced that the first implantation of its breakthrough technology, the TricValve® Transcatheter Bicaval Valves System, was recently
P&F Products & Features GmbH gains CE Mark approval for TricValve® Transcatheter Bicaval Valves System
Vienna, May 18th 2021 TricValve® Transcatheter Bicaval Valves System made in Europe Today, P&F Products & Features GmbH announced that it achieved the CE Mark for its medical device, the TricValve® Transcatheter
FDA Grants Break Through Device Designation for TricValve Transcatheter Bicaval Valves System
Designation as Breakthrough Device by the U.S. Food and Drug Administration (FDA) January 6, 2021 — The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough device to P+F Products +
Vienna, February 24th 2022
P&F Products & Features goes U.S. – first implantation of the TricValve Transcatheter Bicaval Valves System
Vienna, May 18th 2021
P&F Products & Features GmbH gains CE Mark approval for TricValve® Transcatheter Bicaval Valves System
SINGAPORE, October 2021
THE STRAITS TIMES: More minimally invasive treatment options available in S´pore for patients with leaky heart valve
VIENNA, December 22nd 2020
TricValve® Transcatheter Bicaval Valves System granted Designation as Breakthrough Device by the U.S. Food and Drug Administration (FDA)
Short Cases
TricValve® Case Madrid
Ramón y Cajal University Hospital
TricValve® Case Salamanca
University Hospital of Salamanca
TricValve® Case Saudi Arabia
Prince Sultan Cardiac Centre